Treatment of cancer using inhibitors of tgf-beta and pd-1

Abstract

The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

What is claimed: 
     
         1 . A method for treating cancer or preventing the recurrence of cancer comprising administering to a subject in need thereof therapeutically effective amounts of an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of Programmed cell death protein 1 (PD-1), wherein the TGFβ inhibitor is an antibody that binds TGFβ1, TGFβ2amd TGFβ3. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the TGFβ inhibitor is an antibody that
 binds to TGFβ1, TGFβ2 with greater affinity than to TGFβ3; 
 neutralizes activity of TGFβ1and TGFβ2 to a greater extent than it neutralizes activity of TGFβ3; and/or 
 binds to TGFβ1, TGFβ2 and TGFβ3 with an affinity Kd of 10 −6  M or less. 
 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The method of any one of  claim 1  wherein the TGFβ inhibitor is an antibody comprising:
 (a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs: 13, 19 and 25, or a variant thereof having at least 85% identity thereto; 
 (b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs: 14, 20 and 26, or a variant thereof having at least 85% identity thereto; 
 (c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs: 15, 21 and 27, or a variant thereof having at least 85% identity thereto; 
 (d) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs: 16, 22 and 28, or a variant thereof having at least 85% identity thereto; 
 (e) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs: 17, 23 and 29, or a variant thereof having at least 85% identity thereto; and 
 (f) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs: 18, 24 and 30, or a variant thereof having at least 85% identity thereto. 
 
     
     
         7 . The method of  claim 6  wherein the TGFβ inhibitor is an antibody that comprises an amino acid sequence at least 85% identical to a heavy chain variable region amino acid sequence set forth in SEQ ID NOs: 2, 6 and 10. 
     
     
         8 . The method of  claim 7  wherein the antibody further comprises an amino acid sequence at least 85% identical to a light chain variable region amino acid sequence set forth in SEQ ID NOs: 4, 8 and 12. 
     
     
         9 . The method of  claim 1  wherein the TGFβ inhibitor is an antibody comprising: 
       I.
 a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19, or a variant thereof in which one or two amino acids have been changed; 
 b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20, or a variant thereof in which one or two amino acids have been changed; 
 c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21, or a variant thereof in which one or two amino acids have been changed; 
 d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22, or a variant thereof in which one or two amino acids have been changed; 
 e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23, or a variant thereof in which one or two amino acids have been changed; and 
 f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24, or a variant thereof in which one or two amino acids have been changed; 
 
       II.
 a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 13, or a variant thereof in which one or two amino acids have been changed; 
 b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 14, or a variant thereof in which one or two amino acids have been changed; 
 c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 15, or a variant thereof in which one or two amino acids have been changed; 
 d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 16, or a variant thereof in which one or two amino acids have been changed; 
 e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 17, or a variant thereof in which one or two amino acids have been changed; and 
 f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 18, or a variant thereof in which one or two amino acids have been changed; or 
 
       III.
 a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 25, or a variant thereof in which one or two amino acids have been changed; 
 b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 26, or a variant thereof in which one or two amino acids have been changed; 
 c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 27, or a variant thereof in which one or two amino acids have been changed; 
 d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 28, or a variant thereof in which one or two amino acids have been changed; 
 e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 29, or a variant thereof in which one or two amino acids have been changed; and 
 f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 30, or a variant thereof in which one or two amino acids have been changed. 
 
     
     
         10 - 11 . (canceled) 
     
     
         12 . The method of  claim 9  wherein the antibody comprises:
 i) an amino acid sequence at least 90% identical to a heavy chain variable region amino acid sequence set out in SEQ ID NO: 6 and an amino acid sequence at least 90% identical to a light chain variable region amino acid sequence set out in SEQ ID NO: 8.; or 
 ii) an amino acid sequence at least 90% identical to a heavy chain variable region amino acid sequence set out in SEQ ID NO: 10 and an amino acid sequence at least 90% identical to a light chain variable region amino acid sequence set out in SEQ ID NO: 12.; or 
 iii) an amino acid sequence at least 90% identical to a heavy chain variable region amino acid sequence set out in SEQ ID NO: 2 and an amino acid sequence at least 90% identical to a light chain variable region amino acid sequence set out in SEQ ID NO:4. 
 
     
     
         13 - 14 . (canceled) 
     
     
         15 . The method of  claim 9  wherein the antibody further comprises a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof. 
     
     
         16 . The method of  claim 15  further comprising a human light chain constant region. 
     
     
         17 . The method of  claim 1 , wherein the PD-1 inhibitor is an antibody that binds PD-1. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the cancer is selected from the group consisting of esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage IIIA skin melanoma; stage IIIB skin melanoma, stage IIIC skin melanoma; stage IV skin melanoma, malignant melanoma of head and neck, lung cancer, non small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, hodgkin's lymphoma, follicular lymphoma, non-hodgkin's lymphoma, advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission; adult acute myeloid leukemia with Inv(16)(p13.1q22); CBFB-MYH11; adult acute myeloid leukemia with t(16;16)(p13.1;q22); CBFB-MYH11; adult acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1; adult acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, richter's syndrome; waldenstrom macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma; metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma; stage III merkel cell carcinoma; stage IV merkel cell carcinoma, myelodysplastic syndrome, recurrent mycosis fungoidea, Sezary syndrome, lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma, brain lower grade glioma, breast invasive carcinoma, glioblastoma multiforme, melanoma, thyroid, rectum adenocarcinoma, kidney cancer, renal cancer, liver cancer, acute myeloid leukemia, gastric adenocarcinoma, esophageal adenocarcinoma, uterine corpus endometrioid carcinoma, bladder cancer, kidney cancer, prostate cancer, oral cancer, large intestine cancer and lymphoma. 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 1  wherein
 i) the cancer has a mutation in the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene; 
 ii) the cancer has a mutation in the Harvey rat sarcoma viral oncogene homolog (HRAS) oncogene; 
 iii) the cancer has a mutation in the neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) oncogene; and /or 
 iii) the cancer has mutations in the RAS oncogene. 
 
     
     
         22 - 25 . (canceled) 
     
     
         26 . The method of  claim 1  comprising reducing tumor size, tumor burden or metastasis in the subject. 
     
     
         27 - 28 . (canceled) 
     
     
         29 . The method of  claim 1  wherein the PD-1 inhibitor and the TGFβ inhibitor are formulated in a pharmaceutical composition. 
     
     
         30 . The method of  claim 29  wherein the inhibitors are in the same composition or in a separate composition. 
     
     
         31 . (canceled) 
     
     
         32 . The method of  claim 1  wherein the inhibitors are administered concurrently, at separate times or consecutively. 
     
     
         33 . (canceled) 
     
     
         34 . The method of  claim 1  wherein the administration prevents the recurrence of cancer in a subject that has received inhibitor therapy. 
     
     
         35 . The method of  claim 1 , wherein the administration
 i) increases the number of natural killer (NK) cells in a tumor and/or improves NK cell cytolytic activity;   ii) decreases the number of regulatory T cells in a tumor and/or inhibits regulatory T cell function;   iii) increases the number of cytotoxic T cells (CTLs) in a tumor and/or enhances CTL function; and/or   iv) increases the number of type 2 dendritic cells (DC2) in a tumor.   
     
     
         36 - 39 . (canceled) 
     
     
         40 . The method of  claim 1  wherein the TGFβ inhibitor is administered in a dose range of 0.1 to 15 mg/kg and the PD-1 inhibitor is administered in a dose range from 0.1 to 15 mg/kg. 
     
     
         41 . (canceled) 
     
     
         42 . A method for increasing the ratio of effector T cells to regulatory T cells in a tumor comprising administering to a subject in need thereof therapeutically effective amounts of an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of Programmed cell death protein 1 (PD-1).